表没食子儿茶素没食子酸酯防治Ⅲ期乳腺癌患者放射性皮肤损伤的临床回顾性研究  

Clinical retrospective study of epigallocatechin gallate on radiation-induced skin injury in patients with stageⅢbreast cancer

作　　者：马曹秀 赵汉玺 李晓琳 邢力刚 朱婉琦 MA Caoxiu;ZHAO Hanxi;LI Xiaolin;XING Ligang;ZHU Wanqi(Department of Oncology,Affiliated Hospital of Southwest Medical University,Luzhou,Sichuan646000,China;Shandong Cancer Hospital and Institute,Shandong First Medical University and Shandong Academy of MedicalSciences,Jinan,Shandong250117,China)

机构地区：[1]西南医科大学附属医院肿瘤科,四川泸州646000 [2]山东省肿瘤防治研究院(山东省肿瘤医院,放射肿瘤科),山东第一医科大学(山东省医学科学院),山东济南250117 [3]山东省肿瘤防治研究院(山东省肿瘤医院,科教外事部),山东第一医科大学(山东省医学科学院),山东济南250117

出　　处：《中华肿瘤防治杂志》2023年第20期1230-1235,共6页Chinese Journal of Cancer Prevention and Treatment

基　　金：国家自然科学基金(82003233);山东省中医药科技项目(Z-2023092);济南市科技计划(202019163)。

摘　　要：目的探讨放射防护剂表没食子儿茶素没食子酸酯(EGCG)对III期乳腺癌术后放疗患者局部正常损伤及远期安全的影响。方法选取2014-11-01-2019-06-30山东省肿瘤医院收治且符合入排标准的43例接受EGCG预防应用的Ⅲ期女性乳腺癌术后放疗患者纳入病例组,按照入院时间相近、分期相同、年龄相近进行1:1配对,43例常规放疗防护患者纳入对照组。分析2组放疗期间放射治疗肿瘤学组(RTOG)评分、放射性皮炎(RID)出现时间及放射性皮炎指数(RIDI)。对比2组远期安全性,包括无病生存期(DFS)、总生存期、局部复发率及远处转移率。结果2组放疗期间RTOG评分差异有统计学意义,F=9.611,P=0.003。病例组RID出现时间为(3.19±0.91)周,晚于对照组的(2.67±0.84)周,t=2.719,P=0.008。病例组平均RIDI为2.56±1.14,低于对照组的3.36±1.16,t=-3.232,P=0.002。病例组平均DFS为(60.87±4.74)个月,对照组为(62.52±5.44)个月,差异无统计学意义,t=0.097,P=0.756。病例组和对照组平均总生存期分别为(66.71±3.95)和(76.28±4.05)个月,t=0.278,P=0.598。病例组患者1、2和4年DFS率分别为86.05%、76.74%和71.37%,对照组患者分别为88.01%、73.35%和65.45%,差异无统计学意义,χ^(2)=0.097,P=0.756。病例组和对照组4年无局部复发生存率分别为90.70%和83.36%,χ^(2)=0.777,P=0.378;4年无远处转移生存率分别为70.31%和63.11%,χ^(2)=0.278,P=0.598。结论预防性应用EGCG液可降低Ⅲ期乳腺癌患者的放射性皮肤损伤评分,截至随访结束未影响放疗的疗效。EGCG是乳腺癌放射治疗中安全可行的放射性皮肤损伤预防方案。Objective To investigate the effect of radiation protective agent epigallocatechin gallate(EGCG)on radiation dermatitis and long-term safety in radiotherapy for stageⅢbreast cancer.Methods From November 1,2014to June 30,2019,43female patients with stageⅢbreast cancer who received postoperative radiotherapy in Shandong Cancer Hospital and met the admission criteriav@L'-v@for EGCG prophylaxis were selected and included in the case group.According to the similar admission time,the same stage,and the similar age,1∶1matching was performed.Forty-three patients with conventional radiotherapy were included in the control group.We analyzed the Radiation Therapy Oncology Group(RTOG)score,the onset time of radiation dermatitis(RID),and the radiodermatitis index(RIDI)of two groups during radiotherapy.We compared the long-term safety of two groups,including disease-free survival(DFS),overall survival,local recurrence rate,and distant metastasis rate.The difference in RTOG scores between the two groups during radiotherapy was statistically significant,with F=9.611and P=0.003.The occurrence time of RID in the case group was(3.19±0.91)weeks,later than(2.67±0.84)weeks in the control group,t=2.719,P=0.008.The average RIDI of the case group was 2.56±1.14,lower than the control group's 3.36±1.16,t=-3.232,P=0.002.The average DFS of the case group was(60.87±4.74)months,while the control group was(62.52±5.44)months,with no statistically significant difference,t=0.097,P=0.756.The average overall survival time of the case group and the control group was(66.71±3.95)and(76.28±4.05)months,respectively,t=0.278,P=0.598.The 1-year,2-year,and 4-year DFS rates of the case group patients were 86.05%/,76.74%and 71.37%,respectively,while the control group patients were 88.01%,73.35%and 65.45%,respectively,with no statistically significant difference,χ^(2)=0.097,P=0.756.The 4-year local recurrence free survival rates of the case group and the control group were 90.70%and 83.36%,respectively,χ^(2)=0.777,P=0.378;The 4-year distant meta

关 键 词：表没食子儿茶素没食子酸酯 乳腺肿瘤 放射性皮肤炎 总生存期 

分 类 号：R737.9[医药卫生—肿瘤]